Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Magdalena Chodkowska-Michalowska has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Sarnowska

    Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawinskiego 5 Street, 02-106 Warsaw, Poland

    7 shared publications
  • Agnieszka Smolinska

    Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland

    3 shared publications
  • Aleksandra Bzinkowska

    Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland

    3 shared publications
  • Anna Sarnowska

    Mossakowski Medical Research Institute, Polish Academy of Sciences

    2 shared publications
  • Klaudia Radoszkiewicz

    Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland

    2 shared publications
  • Monika Sypecka

    Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland

    2 shared publications

Latest Publications

  • Open Access

    Not All EVs Are Equal: Functional Heterogeneity of Extracellular Vesicles in Neuroregenerative Therapies

    by Magdalena Chodkowska-Michalowska, Oliwia Hawryluk, Szymon Lakomy, Anna Slysz, Anna Sarnowska

    Extracellular vesicles (EVs) are increasingly being investigated as cell-free therapies for neurological diseases. However, their clinical application remains limited by biological and functional heterogeneity. EVs should therefore not be considered as a single, uniform therapeutic product defined only by their cell of origin, size, or conventional vesicle classification. EV composition and activity are influenced by extrinsic factors, including donor and tissue source, culture conditions, and isolation procedures, as well as by intrinsic mechanisms of vesicle biogenesis and selective cargo loading. Some vesicles may have beneficial therapeutic effects, whereas others may show little biological activity or act on unintended cellular targets. For this reason, EVs may be better classified according to biological function rather than only physical properties or cellular origin. A functionality-based classification could improve potency assessment, dose selection, reproducibility, and the development of consistent EV-based products. EV properties can be modulated by selecting appropriate parental cells, modifying culture conditions, or using genetic or metabolic engineering to alter EV production and cargo. Single-vesicle approaches can reveal differences between EV subpopulations and identify those responsible for specific biological effects. Overall, understanding EV heterogeneity may provide a rational basis for developing reproducible and disease-specific EV therapies for neurological and neurodegenerative disorders.

  • Open Access

    CD271 Identifies a Subpopulation with Enhanced Neural-like Potential Within Wharton Jelly Derived Mesenchymal Stem/Stromal Cells

    by Agnieszka Smolinska, Magdalena Chodkowska-Michalowska, Klaudia Radoszkiewicz, Aleksandra Bzinkowska, Anna Sarnowska

    The heterogenous mesenchymal stem/stromal cells (MSCs) express the surface antigens associated with distinct cell subpopulations. CD271, characteristic of stem cells derived from the neural crest, could indicate cells with a unique phenotype. The study examined whether the CD271+ subpopulation characterized by better stem and neural properties than the heterogeneous MSC population. The initial Wharton jelly-derived MSCs (WJ-MSCs) population was divided into two subpopulation: CD271-positive (WJ-MSC-CD271+) and CD271-negative (WJ-MSC-CD271−) with Fluorescence-Activated Cell Sorting (FACS). We compared the clonogenic potential and neural marker expression under standard culture conditions and in the presence of nerve tissue components—cerebrospinal fluid (CSF) or nerve tissue fragments (hippocampus). FACS allowed the enrichment of CD271+ cells from 1% to approximately 50%. WJ-MSC-CD271+ is characterized by significantly more self-renewal cells and increased expression of neuronal genes than WJ-MSC-CD271−. Under co-culture with CSF or hippocampal fragments, WJ-MSC-CD271+ contained more cells expressing Β-III-tubulin as well. Finally, we reported that stimulation with epithelial growth factor (EGF) and basal fibroblast growth factor (bFGF) enhanced CD271+ numbers in the initial population and stabilized them in further cell culture. WJ-MSC-CD271+ cells showed improved potential for differentiation into neural progenitors, although further research is needed for their potential use in neurological diseases.

  • Open Access

    Enhancing the clinical potential: Quality assessment of adipose tissue-derived Mesenchymal Stem/Stromal Cells for therapeutic use

    by Monika Rytel, Magdalena Chodkowska-Michalowska, Dorota Sulejczak, Natalia Krześniak, Marzena Zychowicz, Anna Sarnowska


  • Open Access

    Exploring the Therapeutic Potential of Dedifferentiated Fat Progenitors (DFATs) in Comparison To the Adipose Derived Stem/Stromal Cells (ASCs)

    by Paulina Rybkowska, Aleksandra Bzinkowska, Magdalena Chodkowska-Michalowska, Klaudia Radoszkiewicz, Anna Sarnowska

    Mesenchymal stem/stromal cells (MSCs) therapy has undoubtedly become one of the most popular treatment methods used in tissue regeneration and bioengineering in both pre-clinical and clinical trials. MSCs-based therapy has been characterized to have several benefits, mainly supporting and accelerating tissue regeneration, but at the same time it is still subjected to certain risks. The ideal MSCs population that could be used for clinical purposes should be characterized by superior homogeneity, proper safety level, and great clinical efficacy with limited or no side effects. Recently discovered, dedifferentiated fat progenitors (DFATs) could be the perfect candidates for regenerative medicine. The growing number of studies indicates DFATs superior properties compared to widely used adipose derived stem/stromal cells (ASCs). Some potentially significant differences between ASCs and DFATs have been observed in the process of isolation, their surface marker expression, proliferation ability, differentiation capacity, and expression of pluripotency-related genes. DFATs have also been shown to pose some beneficial effects in animal studies, for instance, they might contribute to bone and cartilage repair, periodontal tissue regeneration, neovascularization, skin and fat grafting, nerve tissue recovery, and intestine restoration in vivo. However, most of the published reports do not compare DFATs function directly to the well-known and used ASCs. Already found differences are inconsistent and not evaluated. Despite the growing interest in the function of DFATs in recent years, the lack of comprehensive and comparative analyses with ASCs represents a significant gap in the current literature. Therefore, it seems reasonable to organize existing data and evaluate the therapeutic potential of DFATs in comparison to the widely used ASCs. In this review, we summarized the current reports considering DFATs therapeutic properties both in vitro and in vivo. To make a clear conclusion if DFATs should be considered more beneficial, we also focused on comparing their features to the already well-investigated function of ASCs.

  • Open Access

    Safety and biodistribution of mesenchymal stromal/stem cells and biocompatible neurotrophin-releasing polyelectrolyte nanoparticles as a preclinical study in amyotrophic lateral sclerosis (ALS) cell therapy

    by Emilia Sinderewicz, Maria Dabkowska, Anna Sarnowska, Joanna Staszkiewicz-Chodor, Dorota Mystkowska, Piotr Holak, Igor Drozd, Magdalena Chodkowska-Michalowska, Monika Rytel, Edyta Paczkowska, et al.

    Amyotrophic lateral sclerosis (ALS) is a multifactorial disease that complicates the identification of unique therapeutic targets. Stem cells and neurotrophins hold therapeutic promise due to their neuroprotective and anti-inflammatory roles. This study preclinically evaluated the safety of mesenchymal stem cells (MSCs) and neurotrophin-releasing polyelectrolyte nanoparticles (NTs) as potential adjuvant therapies in a porcine model. Four groups of castrated male pigs were used. Group I (control) received saline and pegylated NT3-BDNF nanoparticles. Group II received adipose-derived stem cells (ASCs), Group III Wharton’s jelly-derived MSCs (WJ-MSCs), each followed by NT3-BDNF nanoparticles, while Group IV underwent only spinal puncture. Treatments were administered intrathecally. Safety was assessed using MRI, hematological and biochemical parameters, and cerebrospinal fluid analysis. Cell localization was studied with iron-label staining, and tissue integrity was evaluated histologically. Biochemical tests revealed no significant blood parameter changes. C-reactive protein (CRP) levels decreased after NTs and NT–MSC combinations, indicating an anti-inflammatory effect. Biodistribution analysis showed MSC migration via cerebrospinal fluid and accumulation around the spinal cord and brain. MRI and behavioral monitoring confirmed the absence of adverse effects. These findings demonstrate that MSC therapy combined with neurotrophin-releasing nanoparticles is safe and feasible as adjunct therapy for ALS.

  • Open Access

    Stemness properties of SSEA-4+ subpopulation isolated from heterogenous Wharton’s jelly mesenchymal stem/stromal cells

    by Agnieszka Smolinska, Magdalena Chodkowska, Agata Kominek, Jakub Janiec, Katarzyna Piwocka, Dorota Sulejczak, Anna Sarnowska

    Background: High heterogeneity of mesenchymal stem/stromal cells (MSCs) due to different degrees of differentiation of cell subpopulations poses a considerable challenge in preclinical studies. The cells at a pluripotent-like stage represent a stem cell population of interest for many researchers worldwide, which is worthy of identification, isolation, and functional characterization. In the current study, we asked whether Wharton’s jelly-derived MSCs (WJ-MSCs) which express stage-specific embryonic antigen-4 (SSEA-4) can be considered as a pluripotent-like stem cell population.Methods: SSEA-4 expression in different culture conditions was compared and the efficiency of two cell separation methods were assessed: Magnetic Activated Cell Sorting (MACS) and Fluorescence Activated Cell Sorting (FACS). After isolation, SSEA-4+ cells were analyzed for the following parameters: the maintenance of the SSEA-4 antigen expression after cell sorting, stem cell-related gene expression, proliferation potential, clonogenicity, secretome profiling, and the ability to form spheres under 3D culture conditions.Results: FACS allowed for the enrichment of SSEA-4+ cell content in the population that lasted for six passages after sorting. Despite the elevated expression of stemness-related genes, SSEA-4+ cells neither differed in their proliferation and clonogenicity potential from initial and negative populations nor exhibited pluripotent differentiation repertoire. SSEA-4+ cells were observed to form smaller spheroids and exhibited increased survival under 3D conditions.Conclusion: Despite the transient expression of stemness-related genes, our findings could not fully confirm the undifferentiated pluripotent-like nature of the SSEA-4+ WJ-MSC population cultured in vitro.


  • Open Access

    Deciphering the impact of cerebrospinal fluid on stem cell fate as a new mechanism to enhance clinical therapy development

    by Klaudia Radoszkiewicz, Aleksandra Bzinkowska, Magdalena Chodkowska, Paulina Rybkowska, Monika Sypecka, Ilona Zembrzuska-Kaska, Anna Sarnowska

    Neural stem cells (NSCs) hold a very significant promise as candidates for cell therapy due to their robust neuroprotective and regenerative properties. Preclinical studies using NSCs have shown enough encouraging results to perform deeper investigations into more potential clinical applications. Nevertheless, our knowledge regarding neurogenesis and its underlying mechanisms remains incomplete. To understand them better, it seems necessary to characterize all components of neural stem cell niche and discover their role in physiology and pathology. Using NSCs in vivo brings challenges including limited cell survival and still inadequate integration within host tissue. Identifying overlooked factors that might influence these outcomes becomes pivotal. In this review, we take a deeper examination of the influence of a fundamental element that is present in the brain, the cerebrospinal fluid (CSF), which still remains relatively unexplored. Its role in neurogenesis could be instrumental to help find novel therapeutic solutions for neurological disorders, eventually advancing our knowledge on central nervous system (CNS) regeneration and repair.


  • Open Access

    Promising Markers in the Context of Mesenchymal Stem/Stromal Cells Subpopulations with Unique Properties

    by Agnieszka Smolinska, Aleksandra Bzinkowska, Paulina Rybkowska, Magdalena Chodkowska, Anna Sarnowska

    The heterogeneity of the mesenchymal stem/stromal cells (MSCs) population poses a challenge to researchers and clinicians, especially those observed at the population level. What is more, the lack of precise evidences regarding MSCs developmental origin even further complicate this issue. As the available evidences indicate several possible pathways of MSCs formation, this diverse origin may be reflected in the unique subsets of cells found within the MSCs population. Such populations differ in specialization degree, proliferation, and immunomodulatory properties or exhibit other additional properties such as increased angiogenesis capacity. In this review article, we attempted to identify such outstanding populations according to the specific surface antigens or intracellular markers. Described groups were characterized depending on their specialization and potential therapeutic application. The reports presented here cover a wide variety of properties found in the recent literature, which is quite scarce for many candidates mentioned in this article. Even though the collected information would allow for better targeting of specific subpopulations in regenerative medicine to increase the effectiveness of MSC-based therapies.


  • Critical factors responsible for the therapeutic effect of mesenchymal stem/stromal cells in central nervous system disorders

    by Anna Figiel-Dąbrowska, Monika Sypecka, Magdalena Chodkowska, Anna Sarnowska

    Nowadays it is observed that the number of stem-cell based experimental therapies in neurodegenerative disorders is massively increasing. Most of the clinical trials registered to date have been based on autologous mesenchymal stem/stromal cells (MSC) obtained from somatic tissues. In the...